Abstract
Survival difference associated with controlled-release oxycodone analgesic therapy for oxaliplatin-induced peripheral neuropathy in advanced colorectal cancer patients
Highlights
The incidence of colorectal cancer (CRC) is relatively high in many developed countries
Even though oxaliplatin is active against advanced CRC, it causes significant chemotherapy-induced peripheral neuropathy (CIPN), which is a potential dose-limiting side effect of this drug [3,4]
We reported that controlled-release oxycodone (CR oxycodone) was effective for painful oxaliplatin-induced peripheral neuropathy (OIPN) and contributed to patients tolerating extended FOLFOX therapy in advanced CRC patients [10]
Summary
The incidence of colorectal cancer (CRC) is relatively high in many developed countries. Deaths from CRC have decreased gradually over the past several years. This trend is observed in many developed countries. It is possible that development of new anti-cancer therapeutic options is one of the most important contributory factors in the decreased mortality rate and improved survival in CRC patients. Oxaliplatin is commonly used to treat CRC that has spread or metastasized [1,2]. It is usually given in combination, with other anticancer agents (5-fluorouracil and leucovorin) as the FOLFOX chemotherapeutic protocol. Even though oxaliplatin is active against advanced CRC, it causes significant chemotherapy-induced peripheral neuropathy (CIPN), which is a potential dose-limiting side effect of this drug [3,4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
